Louisiana's Top Court Rules For Johnson & Johnson In Appeal Of Risperdal Suit

Johnson & Johnson won an appeal in Louisiana Supreme Court on Tuesday over its marketing of anti-psychotic drug Risperdal as the court overturned a ruling that would have imposed a $258 million penalty on the company. The ruling said that the Louisiana Attorney General, James Caldwell, failed to prove that Janssen Pharmaceutical Inc, part of J&J, violated state law when it misrepresented through off-label statements the potential risk of side effects of the drug. The Louisiana case was not part of a broader $2.2 billion settlement that J&J had made last fall with the U.S. Department of Justice regarding marketing practices for the drug.

Help employers find you! Check out all the jobs and post your resume.